SG10201702828TA - Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof - Google Patents
Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereofInfo
- Publication number
- SG10201702828TA SG10201702828TA SG10201702828TA SG10201702828TA SG10201702828TA SG 10201702828T A SG10201702828T A SG 10201702828TA SG 10201702828T A SG10201702828T A SG 10201702828TA SG 10201702828T A SG10201702828T A SG 10201702828TA SG 10201702828T A SG10201702828T A SG 10201702828TA
- Authority
- SG
- Singapore
- Prior art keywords
- symptoms associated
- behavioral
- prophylactic
- salt
- therapeutic agent
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title 2
- 230000003542 behavioural effect Effects 0.000 title 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 title 1
- 229960001210 brexpiprazole Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261718305P | 2012-10-25 | 2012-10-25 | |
US201361782467P | 2013-03-14 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201702828TA true SG10201702828TA (en) | 2017-05-30 |
Family
ID=49585556
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201503152TA SG11201503152TA (en) | 2012-10-25 | 2013-10-24 | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
SG10201702828TA SG10201702828TA (en) | 2012-10-25 | 2013-10-24 | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201503152TA SG11201503152TA (en) | 2012-10-25 | 2013-10-24 | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
Country Status (22)
Country | Link |
---|---|
US (4) | US20150272946A1 (es) |
EP (2) | EP3848033A1 (es) |
JP (5) | JP6329140B2 (es) |
KR (1) | KR102245016B1 (es) |
CN (4) | CN112402421A (es) |
AR (1) | AR093247A1 (es) |
AU (1) | AU2013335613B2 (es) |
BR (1) | BR112015008759A2 (es) |
CA (1) | CA2889196C (es) |
EA (1) | EA201590808A1 (es) |
HK (1) | HK1212609A1 (es) |
IL (1) | IL238402B (es) |
JO (2) | JOP20210047A1 (es) |
MX (1) | MX371279B (es) |
MY (1) | MY180185A (es) |
NZ (1) | NZ708321A (es) |
PH (1) | PH12015500925B1 (es) |
SG (2) | SG11201503152TA (es) |
TW (1) | TWI643620B (es) |
UA (1) | UA116549C2 (es) |
WO (1) | WO2014065437A1 (es) |
ZA (1) | ZA201503640B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101875961B (zh) | 2003-07-22 | 2015-01-07 | 艾尼纳制药公司 | 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物 |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
EP2190844B3 (en) | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
NO2364142T3 (es) | 2008-10-28 | 2018-06-16 | ||
BR112016024510A2 (pt) | 2014-04-22 | 2017-08-15 | H Lundbeck As | ?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit? |
WO2016115144A1 (en) * | 2015-01-12 | 2016-07-21 | Reviva Pharmaceuticals Inc. | Methods for treating alzheimer's disease |
WO2016115150A1 (en) * | 2015-01-12 | 2016-07-21 | Reviva Pharmaceuticals Inc. | Methods for treating psychosis associated with parkinson's disease |
AU2016276966A1 (en) | 2015-06-12 | 2018-01-18 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder |
JP2018520187A (ja) * | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体 |
CN105175401A (zh) * | 2015-10-16 | 2015-12-23 | 北京康立生医药技术开发有限公司 | 一种依匹哌唑的制备方法 |
CN105541819B (zh) * | 2016-02-04 | 2018-09-14 | 浙江永宁药业股份有限公司 | 一种依匹唑派的制备方法及其中间体和中间体的制备方法 |
CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
KR20200110317A (ko) | 2017-12-05 | 2020-09-23 | 선오비온 파마슈티컬스 인코포레이티드 | 결정형 및 이의 제조 방법 |
EP3720434A4 (en) | 2017-12-05 | 2021-09-01 | Sunovion Pharmaceuticals Inc. | NON-RACEMIC MIXTURES AND THEIR USE |
EP3501506B1 (en) | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
JPWO2021029020A1 (es) * | 2019-08-13 | 2021-02-18 | ||
BR112022026067A2 (pt) * | 2020-06-24 | 2023-01-17 | Univ Hokkaido Nat Univ Corp | Agentes de proteção de células endoteliais vasculares, da barreira hematoencefálica da medula espinhal e do sistema nervoso central, e, composição farmacêutica para prevenir e/ou tratar uma doença acompanhada de um distúrbio da barreira hematoencefálica da medula espinhal |
CN112137994B (zh) * | 2020-09-15 | 2022-10-14 | 中山大学 | 小分子化合物在制备抗丝状病毒药物中的应用 |
US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
AR085840A1 (es) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona |
TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
EP2822136B1 (en) * | 2013-07-03 | 2018-08-29 | Siemens Aktiengesellschaft | Method and arrangement for transferring electrical power for subsea applications |
-
2012
- 2012-10-25 JO JOP/2021/0047A patent/JOP20210047A1/ar unknown
-
2013
- 2013-10-24 AU AU2013335613A patent/AU2013335613B2/en active Active
- 2013-10-24 CN CN202011339120.6A patent/CN112402421A/zh active Pending
- 2013-10-24 NZ NZ708321A patent/NZ708321A/en unknown
- 2013-10-24 EA EA201590808A patent/EA201590808A1/ru unknown
- 2013-10-24 CN CN201380055961.6A patent/CN104755082A/zh active Pending
- 2013-10-24 AR ARP130103867A patent/AR093247A1/es unknown
- 2013-10-24 TW TW102138482A patent/TWI643620B/zh active
- 2013-10-24 CN CN202210498926.2A patent/CN114712360A/zh active Pending
- 2013-10-24 MY MYPI2015701327A patent/MY180185A/en unknown
- 2013-10-24 UA UAA201505106A patent/UA116549C2/uk unknown
- 2013-10-24 US US14/438,335 patent/US20150272946A1/en not_active Abandoned
- 2013-10-24 KR KR1020157013570A patent/KR102245016B1/ko active IP Right Grant
- 2013-10-24 EP EP21159914.7A patent/EP3848033A1/en active Pending
- 2013-10-24 JO JOP/2013/0313A patent/JOP20130313B1/ar active
- 2013-10-24 MX MX2015005174A patent/MX371279B/es active IP Right Grant
- 2013-10-24 BR BR112015008759A patent/BR112015008759A2/pt not_active Application Discontinuation
- 2013-10-24 JP JP2015521734A patent/JP6329140B2/ja active Active
- 2013-10-24 CA CA2889196A patent/CA2889196C/en active Active
- 2013-10-24 WO PCT/JP2013/079480 patent/WO2014065437A1/en active Application Filing
- 2013-10-24 EP EP13792110.2A patent/EP2911670A1/en not_active Withdrawn
- 2013-10-24 SG SG11201503152TA patent/SG11201503152TA/en unknown
- 2013-10-24 SG SG10201702828TA patent/SG10201702828TA/en unknown
- 2013-10-24 CN CN201810366157.4A patent/CN108578408A/zh active Pending
-
2015
- 2015-04-21 IL IL238402A patent/IL238402B/en active IP Right Grant
- 2015-04-24 PH PH12015500925A patent/PH12015500925B1/en unknown
- 2015-05-22 ZA ZA2015/03640A patent/ZA201503640B/en unknown
-
2016
- 2016-01-19 HK HK16100569.3A patent/HK1212609A1/zh unknown
-
2017
- 2017-03-28 US US15/471,429 patent/US20170258787A1/en not_active Abandoned
-
2018
- 2018-03-29 JP JP2018065319A patent/JP2018138555A/ja active Pending
-
2019
- 2019-06-28 US US16/456,334 patent/US20190314367A1/en not_active Abandoned
- 2019-10-29 JP JP2019195831A patent/JP2020045345A/ja active Pending
-
2021
- 2021-07-19 JP JP2021118416A patent/JP2021181448A/ja active Pending
-
2022
- 2022-07-21 US US17/869,993 patent/US20220370442A1/en active Pending
-
2023
- 2023-05-30 JP JP2023088455A patent/JP2023123441A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212609A1 (zh) | 含有依匹唑派或其鹽的用於與神經變性疾病相關的行為和精神症狀或與精神疾病相關的衝動症狀的預防和/或治療劑 | |
IL274988A (en) | Carbamoylpyridone-polycyclic compounds and their pharmaceutical use | |
HK1207990A1 (en) | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease ror | |
IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
HK1203977A1 (en) | Enhancement of transport of therapeutic molecules across the blood brain barrier | |
GB2492487B (en) | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders | |
EP2856421A4 (en) | SYSTEMS AND METHODS FOR TRANSPARENT MEDICAL TREATMENT DELIVERY | |
HUS2000020I1 (hu) | Ciklezonid a légúti betegségek kezelésére lovaknál | |
IL232824A0 (en) | Medical and/or diagnostic nanocarriers targeting mmp | |
GB201322302D0 (en) | Back scattering inspection system for human body | |
ZA201603118B (en) | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | |
HK1218882A1 (zh) | 用於治療神經退化疾病和其它疾病的組合治療劑和方法 | |
EP2903436A4 (en) | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE NEURODAURATIVE | |
GB201317550D0 (en) | Use of Enalaprilat for treatment of neurodegenerative diseases |